Zopapogene imadenovec-drba (Papzimeos) — coverage criteria for recurrent respiratory papillomatosis
Customize your policy alerts
Sign up for all Blue Cross Blue Shield - North Carolina policy alerts
Know when Blue Cross Blue Shield - North Carolina releases new policies or updates existing guidance.
Monitor payer policy activity
Medical necessity and site-of-care criteria for coverage of zopapogene imadenovec-drba (Papzimeos) subcutaneous injections for adults with recurrent respiratory papillomatosis under Blue Cross NC.
Reformatted criteria clarifying histological diagnosis and presence of laryngotracheal papillomas; modified prior requirement about prior debulking procedures and prior therapies to a broader '3 or more interventions' statement and consolidated surgical debulking timing.
Added revenue codes 0891 and 0892 associated with policy HCPCS codes.
Coverage Criteria
Medical Necessity Criteria
Covered when ALL of the following are met
Age and diagnosis
- HPV status: Patient has either human papillomavirus (HPV) type 6 or 11
medical record documentation required
- Anatomic involvement: Presence of laryngotracheal papillomas
medical record documentation required
medical record documentation required
medical record documentation required
medical record documentation required
medical record documentation required
medical record documentation required
medical record documentation required
medical record documentation required
medical record documentation required
medical record documentation required
see site-of-care criteria
When coverage is available and all medical necessity criteria are met for zopapogene imadenovec-drba (Papzimeos), distribution from a specialty pharmacy provider may be required due to cost and site-of-care logistics. Providers should contact Blue Cross NC to coordinate specialty pharmacy distribution and prior authorization as needed to ensure coverage.
Requests that do not meet all of the listed medical necessity criteria are not eligible for coverage. Key prerequisites include: patient age 18 years or older, a confirmed histological diagnosis of recurrent respiratory papillomatosis (RRP), documented infection with HPV type 6 or 11, presence of laryngotracheal papillomas, and documentation of 3 or more interventions in the prior 12 months (e.g., surgery, systemic therapies such as bevacizumab, or intralesional cidofovir). Additional required elements that, if missing, may render a request non-covered include required surgical debulking timing, relevant HBV/HCV laboratory safety results, immunosuppression management, no prior gene therapy, specialist prescriber documentation, and dosing/quantity within FDA-labeled limits.
Applicable Codes and Limits
| C9399 | Other specified pharmaceuticals (HCPCS listed for Papzimeos in policy) |
| J3490 | Unclassified drugs (HCPCS listed for Papzimeos in policy) |
| J3590 | Unclassified biologics (HCPCS listed for Papzimeos in policy) |
| 0891 | Special Processed Drugs - FDA Approved Cell Therapy (applicable revenue code) |
| 0892 | Special Processed Drugs - FDA Approved Gene Therapy (applicable revenue code) |
Provider Actions and Requirements
Prior Authorization Required — dosing limits
Prior authorization is required for coverage. The requested dose and quantity must be within FDA‑labeled dosing for the indication and must not exceed the maximum units allowed for the duration of approval (maximum: 4 injections — one treatment course per lifetime). Requests for injection/infusion in a hospital setting must also meet Site of Care criteria. Medical record documentation supporting dosing and quantity is required.
- Affected product: zopapogene imadenovec-drba (Papzimeos™) — SC: 5×10^11 PU (1 mL) per injection given four times over a 12‑week interval (dosing schedule: dose 2 at ~2 weeks [no less than 11 days], dose 3 at 6 weeks, dose 4 at 12 weeks).
- HCPCS: C9399 / J3490 / J3590 (as applicable).
- Maximum units = 4 injections (1 treatment course per lifetime).
Missing Required Documentation — denial risk
Requests that do not include the required clinical documentation will be delayed or denied. Missing documentation commonly causing denial or delay includes lack of histological confirmation of RRP, absent HPV typing for types 6 or 11, missing documentation of laryngotracheal papillomas, insufficient documentation of prior interventions, or absent operative notes confirming surgical debulking.
- Examples of missing items that may result in denial or delay: histology report confirming RRP; HPV typing results showing type 6 or 11; documentation of laryngotracheal involvement; operative notes showing surgical debulking; records showing prior interventions in past 12 months; lab results for HBV/HCV within past 3 months when required.
Required Documentation — submit with request
Medical record documentation must be submitted with the request and include all of the following as applicable: histological diagnosis of recurrent respiratory papillomatosis (RRP); HPV typing demonstrating type 6 or 11; documentation of laryngotracheal papillomas; documentation of prior interventions and dates; operative reports confirming surgical debulking before the initial, third, and fourth administrations; vaccination record for HPV if patient is <46 years; prior gene therapy history; specialist involvement (or consultation); and relevant laboratory results (HBV and HCV testing within the past 3 months when required).
- Histology report confirming RRP.
- HPV typing showing type 6 or 11.
- Documentation of laryngotracheal papillomas (e.g., laryngoscopy findings, imaging, operative notes).
- Documentation of ≥3 interventions in prior 12 months (surgery or systemic/intralesional therapies) with dates and descriptions.
- Operative reports showing surgical debulking prior to initial, third, and fourth administrations.
- HPV vaccination record if patient <46 years.
- HBV and HCV lab results within 3 months when required by criteria.
- Documentation that patient has not received prior gene therapy and prescriber is a specialist or has specialist consult.
Prior Interventions Requirement — documented evidence of ≥3 in prior 12 months
Prior to approval, the policy requires evidence of at least three interventions for control of RRP in the prior 12 months (these may include surgical debulking, systemic therapy such as bevacizumab, or intralesional therapies such as cidofovir). Provide specific dates and types of interventions. Failure to document ≥3 interventions in the preceding 12 months will result in denial.
- Acceptable interventions: surgery (debulking), systemic therapies (e.g., bevacizumab), intralesional therapies (e.g., cidofovir).
- Time window: interventions must have occurred within the 12 months prior to the request and be clearly documented in the medical record.
Definitions
Background
Recurrent respiratory papillomatosis (RRP) is an HPV-driven disorder characterized by recurrent benign papillomas of the respiratory tract that commonly involve the larynx and trachea and frequently require repeated surgical and medical interventions to maintain airway patency and control disease. Papzimeos (zopapogene imadenovec-drba) is an FDA-approved gene therapy indicated for adults with RRP to reduce disease burden when specified clinical, virologic, and safety criteria are met. Treatment with Papzimeos is administered as a course of 4 subcutaneous injections over a 12-week interval and is limited to one treatment course per lifetime; prior authorization and documentation of required safety labs and prior interventions are necessary before approval.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.